Nosis Bio Head of Research and Principal Scientist to Present Research on Targeted siRNA Delivery at Oligotherapeutic Society Meeting 2024
We’re thrilled to announce that two of Nosis Biosciences’ abstracts have been accepted for presentation at the 2024 Oligotherapeutic Society Meeting in Montreal, Ontario, taking place from October 6-9, 2024. This conference is a premier event for scientists and industry leaders working at the forefront of oligonucleotide therapeutics, and Nosis Bio is honored to contribute to the program with two pioneering studies focused on enhancing the specificity and functionality of siRNA delivery.
Our Head of Research, Dr. Chad Miller, and Principal Scientist, Dr. Kyler Lugo, will present the following research:
• Deep learning-based design of cell-targeting ligands enables targeted and functional siRNA delivery to lung cell subsets
This study explores how Nosis Bio’s proprietary deep learning algorithms are being used to design cell-specific ligands that direct siRNA precisely to targeted lung cell subsets. By refining targeting to specific lung cells, this approach aims to increase therapeutic efficacy while minimizing off-target effects, marking a significant advancement in siRNA delivery for pulmonary diseases. Nosis will also present data on disease efficacy and safety supporting candidate selection studies for future clinical development.
• Deep learning-based design of delivery vehicles targeting rapidly-internalizing receptors enables functional siRNA delivery
In this work, Dr. Miller will present findings on a proprietary novel delivery approach that leverages deep learning to identify and target receptors known for rapid internalization. This innovative strategy enables siRNA molecules to be delivered functionally to cells, significantly broadening the therapeutic applications of RNA-based treatments.
The 2024 Oligotherapeutic Society Meeting provides an excellent forum to share these advances with the scientific community, sparking conversations that will shape the future of oligonucleotide and RNA therapies. We look forward to connecting with colleagues and experts in Montreal as we continue to push the boundaries of RNA science and targeted medicine.
Stay tuned for updates from the conference as Nosis Bio showcases its commitment to advancing RNA therapeutics for a more precise, impactful approach to healthcare.